Special Considerations for NIDA Funding Opportunities and Awards

Coordination with NIDA Press Office

If your recipient institution wishes to do a press release or is planning media outreach around your Notice of Award (NOA), please closely coordinate with the NIDA Press Office, which can be reached at media@nida.nih.gov. Please note that NIDA and NIH do not publicly discuss any funding or grant until it has been officially posted in NIH RePORTER, which is updated on a weekly basis. We therefore advise that recipients hold all public statements announcing your award (on social media, websites, through the press, etc.) until that time. 

In order to most effectively disseminate research results, advance notice should be given to NIDA that research findings are about to be published so that we may coordinate accurate and timely release to the media, by emailing the NIDA press office at media@nida.nih.gov.This information will be embargoed until the publication date. Any press materials issued by the recipient institution must also adhere to the Acknowledgment of Federal Funding Requirement (as specified in the NIH Grants Policy Statement).

National Advisory Council on Drug Abuse Recommended Guidelines for the Administration of Drugs to Human Subjects

The National Advisory Council on Drug Abuse (NACDA) recognizes the importance of research involving the administration of drugs with abuse potential, and dependence or addiction liability, to human subjects. Potential applicants are encouraged to obtain and review these recommendations of Council before submitting an application that will administer compounds to human subjects. The guidelines are available here - NACDA Guidelines for Administration of Drugs to Human Subjects.

Points to Consider Regarding Tobacco Industry Funding of NIDA Applicants

The National Advisory Council on Drug Abuse (NACDA) encourages NIDA and its grantees to consider the points it has set forth with regard to existing or prospective sponsored research agreements with tobacco companies or their related entities and the impact of acceptance of tobacco industry funding on NIDA's credibility and reputation within the scientific community. Please see Points to Consider Regarding Tobacco Industry Funding of NIDA Applicants

Data Harmonization for Substance Abuse and Addiction via the PhenX Toolkit

 NIDA strongly encourages investigators involved in human-subjects studies to employ a common set of tools and resources that will promote the collection of comparable data across studies and to do so by incorporating the measures from the Core and Specialty collections, which are available in the Substance Abuse and Addiction Collection of the PhenX Toolkit (www.phenxtoolkit.org). Please see NOT-DA-12-008 for further details.

Data Sharing

NIDA strongly encourages investigators to share data with other investigators. NIDA expects that applicants to NIDA funding opportunity announcements:

  1. Submit their data to one of the NIH data archives for sharing;
  2. Include specific required elements in the Resource Sharing Plan including a description of whether and how the consents that will be used to obtain that data will affect the research that can be done with that data;
  3. Include costs attributed to data preparation and submission to a data archive in grant applications.
Establishment of a Standard delta-9-THC Unit to be used in Research

Applications proposing research on cannabis or its main psychotropic constituent delta-9-THC are required to measure and report results using a standard delta-9-THC unit in all applicable human subjects’ research.  The goal is to increase the comparability across cannabis research studies. A standard delta-9-THC unit is defined as any formulation of cannabis plant material or extract that contains 5 milligrams of delta-9-THC.  A justification should be provided for human research that does not propose to use the standard unit. Please see NOT-DA-21-049 for additional details.

Research on State-Legal Cannabis Dispensary Products
Can NIH-supported researchers purchase or possess cannabis products containing > 0.3% delta-9-tetrahydrocannabinol from state-legal cannabis dispensaries for research purposes?
NIH-funded researchers must possess a Schedule I research registration from the Drug Enforcement Administration to conduct research with cannabis products with more than 0.3% delta-9-tetrahydrocannabinol (THC) on a dry weight basis. Purchasing or handling such products without an appropriate registration is a violation of federal law and therefore a violation of the terms/conditions of an NIH research award. NIDA encourages grant applicants to contact the Drug Enforcement Administration with specific questions about whether the DEA would approve a Schedule I research registration for research using such cannabis products obtained from state-legal dispensaries.